Receive Our Newsletter

New Biopharmaceutical Company, Sigilon Therapeutics, Launches

industry_news_banner

Note: The following is an edited version of a press release from Sigilon Therapeutics. Read the press release from Sigilon Therapeutics in it’s entirety here.


Flagship Pioneering, a fully-integrated life science innovation enterprise, recently announced the launch of Sigilon Therapeutics Inc. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer™ technology, a new class of implantable biomaterials that do not trigger fibrosis. The company will develop products that emerge from its discovery platform to treat serious hematologic, enzyme deficiency and endocrine disorders. VentureLabs®, Flagship’s institutional innovation foundry, originated Sigilon Therapeutics and co-founded the company with Professors Daniel Anderson and Robert Langer of MIT’s Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute.

 

 

 

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community